Want to see TSE:DOSE full AI Analyst Report?
Total Valuation
Rapid Dose Therapeutics Corp has a market cap or net worth of C$14.87M. The enterprise value is C$18.72M.
Market CapC$14.87M
Enterprise ValueC$18.72M
Share Statistics
Rapid Dose Therapeutics Corp has 135,181,840 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding135,181,840
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Rapid Dose Therapeutics Corp’s return on equity (ROE) is 0.47 and return on invested capital (ROIC) is 117.10%.
Return on Equity (ROE)0.47
Return on Assets (ROA)-1.03
Return on Invested Capital (ROIC)117.10%
Return on Capital Employed (ROCE)0.42
Revenue Per Employee231.11K
Profits Per Employee-282.47K
Employee Count12
Asset Turnover0.84
Inventory Turnover23.29
Valuation Ratios
The current PE Ratio of Rapid Dose Therapeutics Corp is ―. Rapid Dose Therapeutics Corp’s PEG ratio is 0.14.
PE Ratio―
PS Ratio7.19
PB Ratio-2.78
Price to Fair Value-2.78
Price to FCF-73.51
Price to Operating Cash Flow-47.72
PEG Ratio0.14
Income Statement
In the last 12 months, Rapid Dose Therapeutics Corp had revenue of 2.77M and earned -3.39M in profits. Earnings per share was -0.03.
Revenue2.77M
Gross Profit-956.89K
Operating Income-2.17M
Pretax Income-3.39M
Net Income-3.39M
EBITDA-1.66M
Earnings Per Share (EPS)-0.03
Cash Flow
In the last 12 months, operating cash flow was -311.63K and capital expenditures -899.00, giving a free cash flow of -313.43K billion.
Operating Cash Flow-311.63K
Free Cash Flow-313.43K
Free Cash Flow per Share>-0.01
Dividends & Yields
Rapid Dose Therapeutics Corp pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.23
52-Week Price Change-45.00%
50-Day Moving Average0.10
200-Day Moving Average0.13
Relative Strength Index (RSI)53.59
Average Volume (3m)36.09K
Important Dates
Rapid Dose Therapeutics Corp upcoming earnings date is Jul 24, 2026, Before Open (Confirmed).
Last Earnings DateJun 29, 2026
Next Earnings DateJul 24, 2026
Ex-Dividend Date―
Financial Position
Rapid Dose Therapeutics Corp as a current ratio of 0.04, with Debt / Equity ratio of -74.16%
Current Ratio0.04
Quick Ratio0.02
Debt to Market Cap0.17
Net Debt to EBITDA-3.20
Interest Coverage Ratio-1.78
Taxes
In the past 12 months, Rapid Dose Therapeutics Corp has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Rapid Dose Therapeutics Corp EV to EBITDA ratio is -15.23, with an EV/FCF ratio of -93.08.
EV to Sales9.11
EV to EBITDA-15.23
EV to Free Cash Flow-93.08
EV to Operating Cash Flow-93.39
Balance Sheet
Rapid Dose Therapeutics Corp has C$11.55K in cash and marketable securities with C$5.32M in debt, giving a net cash position of -C$5.31M billion.
Cash & Marketable SecuritiesC$11.55K
Total DebtC$5.32M
Net Cash-C$5.31M
Net Cash Per Share-C$0.04
Tangible Book Value Per Share-C$0.05
Margins
Gross margin is 10.13%, with operating margin of -78.29%, and net profit margin of -122.22%.
Gross Margin10.13%
Operating Margin-78.29%
Pretax Margin-122.22%
Net Profit Margin-122.22%
EBITDA Margin-59.78%
EBIT Margin-78.29%
Analyst Forecast
The average price target for Rapid Dose Therapeutics Corp is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast33.00%
EPS Growth Forecast40.74%